Medical treatment of benign prostatic hyperplasia (BPH) have been accepted from 1990s following the randomized, double blind, placebo controlled studies showing that finasteride (5α reductase inhibitor - 5ARI) and terazosin (α blocker) significantly improved lower urinary tract symptoms (LUTS) and increased Qmax in men with BPH.